| dbo:abstract | - Abexinostat (INN, formerly PCI-24781) is an experimental drug candidate for cancer treatment. It was developed by Pharmacyclics and licensed to Xynomic. and is in Phase II clinical trials for B-cell lymphoma. Pre-clinical study suggests the potential for treatment of different types of cancer as well. Abexinostat exerts its effect as a pan-histone deacetylase inhibitor and inhibits RAD51, which is involved in repairing DNA double strand breaks. (en)
- Abexinostat (INN, anteriormente PCI-24781 o CRA-024781) con fórmula C21H23N3O5, es un candidato a fármaco experimental para el tratamiento del cáncer. Actualmente se encuentra en desarrollo por Pharmacyclics y se encuentra en ensayos clínicos de fase II para el linfoma de células B. Los estudios pre-clínicos sugieren también el potencial para el tratamiento de otros diferentes tipos de cáncer. Abexinostat ejerce su efecto como un inhibidor de la Histona deacetilasa. (es)
|
| dbo:alternativeName | - PCI-24781; CRA-024781 (en)
|
| dbo:iupacName | - 3-[(Dimethylamino)methyl]-N-{2-[4-(hydroxycarbamoyl)phenoxy]ethyl}-1-benzofuran-2-carboxamide (en)
|
| dbo:thumbnail | |
| dbo:wikiPageID | |
| dbo:wikiPageLength | - 7191 (xsd:nonNegativeInteger)
|
| dbo:wikiPageRevisionID | |
| dbo:wikiPageWikiLink | |
| dbp:imagefile | |
| dbp:iupacname | |
| dbp:othernames | - PCI-24781; CRA-024781 (en)
|
| dbp:verifiedfields | |
| dbp:verifiedrevid | |
| dbp:wikiPageUsesTemplate | |
| dcterms:subject | |
| gold:hypernym | |
| rdf:type | |
| rdfs:comment | - Abexinostat (INN, formerly PCI-24781) is an experimental drug candidate for cancer treatment. It was developed by Pharmacyclics and licensed to Xynomic. and is in Phase II clinical trials for B-cell lymphoma. Pre-clinical study suggests the potential for treatment of different types of cancer as well. Abexinostat exerts its effect as a pan-histone deacetylase inhibitor and inhibits RAD51, which is involved in repairing DNA double strand breaks. (en)
- Abexinostat (INN, anteriormente PCI-24781 o CRA-024781) con fórmula C21H23N3O5, es un candidato a fármaco experimental para el tratamiento del cáncer. Actualmente se encuentra en desarrollo por Pharmacyclics y se encuentra en ensayos clínicos de fase II para el linfoma de células B. Los estudios pre-clínicos sugieren también el potencial para el tratamiento de otros diferentes tipos de cáncer. Abexinostat ejerce su efecto como un inhibidor de la Histona deacetilasa. (es)
|
| rdfs:label | - Abexinostat (en)
- Abexinostat (es)
|
| owl:sameAs | |
| prov:wasDerivedFrom | |
| foaf:depiction | |
| foaf:isPrimaryTopicOf | |
| isdbo:wikiPageRedirects of | |
| isdbo:wikiPageWikiLink of | |
| isfoaf:primaryTopic of | |
